Late Brain Oligometastases Diagnosed at Least 36 Months after Cancer Detection are Associated with Favorable Survival Outcome
Open Access
- 3 January 2020
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 12 (1) , e6553
Abstract
The aim of this study was to investigate the impact of a long disease-free interval (at least 36 months from the first diagnosis of cancer) on survival in patients with brain oligometastases (maximum four lesions, no extracranial metastases). This study involves a retrospective analysis in a group of 89 patients treated with different brain-directed approaches. We identified seven patients (8%) with an interval from cancer diagnosis to the development of brain metastases of at least 36 months. The median time interval was five months. The one-year survival rates were 80% (interval of at least 36 months) and 43% (shorter interval), respectively (p = 0.049). Correspondingly, a large difference in actuarial median survival was observed (39.9 months [95% confidence interval, 16.8-63.0 months] versus 9.7 months (95% confidence interval, 6.1-13.3 months). However, the two Kaplan-Meier curves were not statistically significantly different, p = 0.13. In addition to treatment-related differences, the two groups also differed with regard to the type of primary tumor (high versus low rates of non-small cell lung cancer) and gender. Late dissemination was uncommon. The often applied strategy of effective local treatment for patients with brain-only oligometastases is warranted, especially if the disease-free interval had been at least 36 months. Larger studies are needed to fully understand the impact of confounding factors, such as gender and tumor biology.Keywords
This publication has 30 references indexed in Scilit:
- Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain OligometastasesFrontiers in Oncology, 2019
- Presence of Brain Metastases at Initial Diagnosis of Cancer: Patient Characteristics and OutcomeCureus, 2019
- Contemporary Management of 1–4 Brain MetastasesFrontiers in Oncology, 2018
- Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasisNature Communications, 2018
- Clinical Features of Precocious, Synchronous, and Metachronous Brain Metastases and the Role of Tumor ResectionWorld Neurosurgery, 2018
- The Evolving Landscape of Brain MetastasisTrends in Cancer, 2018
- Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trialRadiotherapy and Oncology, 2018
- An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung CancerClinical Lung Cancer, 2014
- Prognostic Scores in Patients with Brain Metastases from Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997